XML 39 R78.htm IDEA: XBRL DOCUMENT v3.20.1
Share-based Compensation - Assumptions Used in Determining Fair Value of Options (Details) - Stock options - $ / shares
1 Months Ended 12 Months Ended
Jul. 31, 2018
Jun. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stock options, restricted stock and performance stock options          
Options granted (in shares)     2,119,708 1,753,539  
Granted (in dollars per share)     $ 2.163 $ 6.786  
Weighted average key assumptions used in determining the fair value of options granted          
Estimated dividend yield (as a percent)     0.00% 0.00% 0.00%
Expected stock price volatility (as a percent)     60.00% 60.00% 60.00%
Weighted-average risk-free interest rate (as a percent)     2.44% 2.75% 2.01%
Expected life of option in years     6 years 29 days 6 years 1 month 17 days 6 years 22 days
Weighted-average option fair value at grant (in dollars per share)     $ 1.24 $ 3.93 $ 4.09
Neos Therapeutics, Inc. 2015 Stock Option and Incentive Plan          
Stock options, restricted stock and performance stock options          
Options granted (in shares)     2,119,708    
Neos Therapeutics, Inc 2018 Inducement Plan | Chief Executive Officer          
Stock options, restricted stock and performance stock options          
Options granted (in shares) 200,000 600,000      
Granted (in dollars per share) $ 5.55 $ 6.20